Cancer treatment has traditionally focused on eliminating tumor cells but faces challenges such as resistance and toxicity. A promising direction involves targeting the tumor microenvironment using CAR T cell immunotherapy, which has shown potential for treating relapsed and refractory cancers but is limited by high costs, resistance, and toxicity, especially in solid tumors. The integration of nanotechnology into ICAM cell therapy, a concept we have named “CAR T nanosymbiosis”, offers new opportunities to overcome these challenges. Nanomaterials can enhance CAR T cell delivery, manufacturing, activity modulation, and targeting of the tumor microenvironment, providing better control and precision. This approach aims to improve the efficacy of CAR T cells against solid tumors, reduce associated toxicities, and ultimately enhance patient outcomes. Several studies have shown promising results, and developing this therapy further is essential for increasing its accessibility and effectiveness. Our “addition by subtraction model” synthesizes these multifaceted elements into a unified strategy to advance cancer treatment paradigms.
We present the case of a 21-year-old male patient with a history of monophasic synovial sarcoma in his left thigh, which was treated with surgical resection, radiotherapy, and chemotherapy with mesna, doxorubicin, and Ifosfamide (MAI protocol). Approximately six years after the end of the oncological treatment, he presented a nodular, polypoid lesion in the left popliteal region, which was painless and fast growing. Ultimately, the biopsy was consistent with atypical vascular proliferation (AVP). Vascular lesions after radiotherapy include a wide spectrum of pathologies that range from benign lesions such as AVP to malignant ones with very poor prognosis such as angiosarcoma, the distinction between one and the other can be difficult, being the determination rearrangement or amplification of gene c-myc, a key to make an accurate diagnosis in case of doubt.
28 June 2023 in Revista Colombiana de Hematología y Oncología
Descripción del caso: se describe el caso de una paciente de 61 años con antecedente de mesotelioma epitelial maligno cT4N0M1 estadio clínico IV en manejo con carboplatino/ pemetrexed por seis ciclos, con progresión, por lo cual inicia manejo con nivolumab. Luego de cuatro ciclos de tratamiento consulta por cuadro de 15 días de aparición de equimosis en miembros inferiores y cefalea intensa, la biometría hemática documenta bicitopenia por anemia moderada 8.9 g/dl y trombocitopenia severa 1000x103/ uL, sin compromiso de línea mieloide o linfoide. Tomografía cerebral con hematoma subdural laminar hemisférico derecho, el cual condicionaba obliteración de los surcos cerebrales hacia la convexidad, valorado por neurocirugía descartando necesidad de intervención. Se realizaron imágenes para evaluación de estado de enfermedad oncológica encontrándose por criterios RECIST 1.1 con enfermedad estable; se decide descartar causas infecciosas, carenciales y autoinmunes los cuales fueron normales, se descarta mieloptisis a través de un aspirado y biopsia de medula ósea, mostrando solo hiperplasia megacariocítica, sin infiltración neoplásica.